Modern immunotherapeutic drugs such as Pembrolizumab and Dostarlimab, which belong to the checkpoint inhibitors (ICIs), revolutionize the treatment of EC by blocking the interaction of the PD-1 receptor with its ligands (PD-L1, PD-L2), leading to the restoration of T lymphocyte activity and enhanced anti-tumor response [27,31,37,38,39]. This evidence concerns the gene PDCD1LG2 and neoplasm.